📊 JRSS Key Takeaways
Is JRSS a Good Investment? Thesis Analysis
JRSS is technically insolvent with negative stockholders' equity of -$197.6K and critically depleted cash reserves of only $1.4K. Despite 101.4% revenue growth to $1.3M, the company burns -$826.1K in operating cash flow and -$1.1M in free cash flow annually, with an operating margin of -36.8% indicating unsustainable losses.
Why Buy JRSS? Key Strengths
- Strong top-line revenue growth of 101.4% YoY demonstrates market traction
- Positive gross profit of $270.2K shows some operational contribution
- Active in healthcare services sector with operational presence
JRSS Investment Risks to Consider
- Negative stockholders' equity (-$197.6K) indicates technical insolvency and balance sheet deterioration
- Critically low liquidity: $1.4K cash with current ratio of 0.78x creates imminent solvency risk
- Massive operating losses (-$485.8K) and negative free cash flow (-$1.1M) indicate unsustainable cash burn
- Operating cash flow of -$826.1K and net margin of -33.0% show business model is unprofitable at scale
- No insider activity in past 90 days and liabilities exceed assets by $200K
Key Metrics to Watch
- Monthly cash burn rate and cash runway (critical given $1.4K position)
- Operating cash flow trend (currently -$826.1K annually)
- Path to stockholders' equity recovery above zero
- Debt covenant compliance and refinancing risk
JRSS Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
JRSS Profitability Ratios
JRSS vs Healthcare Sector
How JRSIS HEALTH CARE Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is JRSS Overvalued or Undervalued?
Based on fundamental analysis, JRSIS HEALTH CARE Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
JRSS Balance Sheet & Liquidity
JRSS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: JRSIS HEALTH CARE Corp's revenue has grown significantly by 56% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
JRSS Growth Metrics (YoY)
JRSS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $222.9K | -$26.9K | $0.00 |
| Q2 2024 | $337.4K | -$60.6K | $0.00 |
| Q1 2024 | $477.0K | $45.4K | $0.00 |
| Q3 2023 | $13.6K | -$119.1K | $-0.02 |
| Q2 2023 | $43.3K | -$105.0K | $-0.02 |
| Q1 2022 | $7.3M | $495.9K | $0.02 |
| Q3 2021 | $10.0M | $314.9K | $0.02 |
| Q2 2021 | $7.0M | $314.9K | $0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
JRSS Capital Allocation
JRSS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for JRSIS HEALTH CARE Corp (CIK: 0001597892)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JRSS
What is the AI rating for JRSS?
JRSIS HEALTH CARE Corp (JRSS) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are JRSS's key strengths?
Claude: Strong top-line revenue growth of 101.4% YoY demonstrates market traction. Positive gross profit of $270.2K shows some operational contribution.
What are the risks of investing in JRSS?
Claude: Negative stockholders' equity (-$197.6K) indicates technical insolvency and balance sheet deterioration. Critically low liquidity: $1.4K cash with current ratio of 0.78x creates imminent solvency risk.
What is JRSS's revenue and growth?
JRSIS HEALTH CARE Corp reported revenue of $1.3M.
Does JRSS pay dividends?
JRSIS HEALTH CARE Corp does not currently pay dividends.
Where can I find JRSS SEC filings?
Official SEC filings for JRSIS HEALTH CARE Corp (CIK: 0001597892) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JRSS's EPS?
JRSIS HEALTH CARE Corp has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JRSS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, JRSIS HEALTH CARE Corp has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JRSS stock overvalued or undervalued?
Valuation metrics for JRSS: ROE of N/A (sector avg: 15%), net margin of -33.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JRSS stock in 2026?
Our dual AI analysis gives JRSIS HEALTH CARE Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is JRSS's free cash flow?
JRSIS HEALTH CARE Corp's operating cash flow is $-826.1K, with capital expenditures of $232.5K. FCF margin is -80.1%.
How does JRSS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -33.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.78 (avg: 2).